CLAIM AMENDMENTS

1-32. (canceled)

33. (currently amended): A method to deliver a synergistic therapeutically effective amount of a fluoropyrimidine/water-soluble camptothecin drug combination to a subject which method comprises administering to said subject a first composition containing a fluoropyrimidine stably associated with ~~a first particulate delivery vehicle and~~ liposomes together with a second composition containing a water-soluble camptothecin stably associated with ~~a second particulate delivery vehicle~~ liposomes wherein the ratio of the fluoropyrimidine and the water soluble camptothecin administered is synergistic,

wherein said stable association maintains, for at least one hour, a synergistic ratio of said fluoropyrimidine and camptothecin in the blood when administered *in vivo*, and

wherein said synergistic ratio is such that when said ratio is provided to cancer cells in an *in vitro* assay over the concentration range at which the fraction of affected cells is 0.20 to 1.00, synergy is exhibited over at least 20% of said range.

34. (currently amended): The method of claim 33 wherein the ~~particulate delivery vehicles~~ liposomes have a mean diameter of between 4.5 nm and 500 nm.

35. (canceled)

36. (previously presented): The method of claim 33 wherein the water-soluble camptothecin is irinotecan (CPT-11), topotecan, 9-aminocamptothecin or lurtotecan.

37. (previously presented): The method of claim 33 wherein the water-soluble camptothecin is a hydrophilic salt of a water-insoluble camptothecin.

38. (previously presented): The method of claim 33 wherein the water-soluble camptothecin is irinotecan (CPT-11) or topotecan.

39. (previously presented): The method of claim 33 wherein the fluoropyrimidine is floxuridine, fluorouracil or UFT (tegafur/uracil).

40. (previously presented): The method of claim 33 wherein the water-soluble camptothecin is irinotecan and said fluoropyrimidine is floxuridine or 5-FU.

41. (previously presented): The method of claim 40 wherein the ratio is 1:1.

42. (previously presented): The method of claim 33 which further comprises administering leucovorin to said subject.

43-44. (canceled)